Which patient would be inappropriate to initiate an anti-hyperlipidemic medication?

Which patient would be inappropriate to initiate an anti-hyperlipidemic medication?

• A. A 30-year-old with history of heart disease
• B. A 57-year-old with cirrhosis due to alcohol abuse
• C. A 44-year-old with recurrent urinary tract infections
• D. A 79-year-old with bilateral cataracts

Answer: (B)

Understanding how safety concerns limit anti-hyperlipidemic therapy helps explain why this patient is inappropriate to start such treatment. Statins and similar drugs are processed by the liver and can cause hepatotoxicity. In cirrhosis, liver function is already impaired, making drug metabolism unpredictable and increasing the risk of liver injury or decompensation. Because of this, initiating an anti-hyperlipidemic medication in someone with alcohol‑related cirrhosis is not appropriate. The other scenarios don’t present the same clear liver-related contraindication: a younger patient with heart disease would typically benefit from lipid-lowering therapy, a patient with recurrent UTIs has no lipid‑disorder safety issue, and cataracts are not an established contraindication to these drugs.

Understanding how safety concerns limit anti-hyperlipidemic therapy helps explain why this patient is inappropriate to start such treatment. Statins and similar drugs are processed by the liver and can cause hepatotoxicity. In cirrhosis, liver function is already impaired, making drug metabolism unpredictable and increasing the risk of liver injury or decompensation. Because of this, initiating an anti-hyperlipidemic medication in someone with alcohol‑related cirrhosis is not appropriate. The other scenarios don’t present the same clear liver-related contraindication: a younger patient with heart disease would typically benefit from lipid-lowering therapy, a patient with recurrent UTIs has no lipid‑disorder safety issue, and cataracts are not an established contraindication to these drugs.